Advanced Filters
noise

Additional Locations, Texas Clinical Trials

A listing of Additional Locations, Texas clinical trials actively recruiting patient volunteers.

Found 553 clinical trials
L Lauren Downing

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells \[DSG3-CAART\] or CD19-specific Chimeric Antigen Receptor T cells \[CABA-201\]) in subjects with active, pemphigus vulgaris

18 years of age All Phase 1/2
V Victoria Shay, MS

Fontan Udenafil Exercise Longitudinal Assessment Trial - 2

This study will evaluate the clinical efficacy and safety of udenafil, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of adolescent who have had the Fontan procedure.

12 - 18 years of age All Phase 3
A Adriana Drada

Promising ROd-cone DYstrophy Gene therapY

This is a two-step, multicenter, Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm, controlled, double-masked, randomized extension phase (Step 2), in subjects with advanced RCD due to a mutation in the RHO, PDE6A, or PDE6B gene.

18 years of age All Phase 1/2
J Julia Kim

Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus

To evaluate the safety and efficacy of the ProTractX3™ DCB for the treatment of benign esophageal strictures.

22 years of age All Phase 3
B Bonnie Ostergren

Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion

This single-center, prospective, randomized study will evaluate the safety and feasibility of Intracardiac echocardiography (ICE)-guided Left atrial appendage closure (LAAC) when compared to the traditional Transesophageal echocardiography (TEE) approach.

18 - 90 years of age All Phase N/A
K Katherine Pennycott, RN

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.

18 years of age All Phase 1/2
R Rhoda Annoh Gordon

MTOR Inhibitors in Older Adults

Over the past decades, healthcare systems face significant challenges to meet the needs of an aging population due to progressive debility, functional decline and chronic diseases development. While there is a growing appreciation of the potential impact of mTOR inhibitors on slowing aging processes, preventing chronic disease and prolonging healthy …

65 - 80 years of age All Phase 1/2
S Study Contact

A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with tofacitinib in adults with moderate and severe ulcerative colitis (UC). Another aim is to learn about treatment with Vedolizumab alone after the double treatment. All participants will receive vedolizumab together …

18 - 65 years of age All Phase 4

Targeted Plasticity Therapy for PTSD

Objectives of this study are to provide continued safety assessment for the ReStore system, and to gain further estimates of the effect size of Vagus Nerve Stimulation (VNS) therapy with Prolonged Exposure Therapy (PE) compared to PE with placebo (sham) stimulation in participants with posttraumatic stress disorder (PTSD)

22 - 79 years of age All Phase N/A
K Kaisha Mofford

Bionic Pancreas in CFRD

This multi-center randomized controlled trial (RCT) will compare efficacy and safety endpoints using the insulin-only configuration of the iLet Bionic Pancreas System (BP) versus a control group using their usual care insulin delivery method and continuous glucose monitoring (CGM) during a 13-week study period in individuals ≥14 years old with …

14 years of age All Phase 3

Simplify language using AI